NYSE - Delayed Quote • USD
Eli Lilly and Company (LLY)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 7:59 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 15 | 15 | 25 | 25 |
| Avg. Estimate | 2.47 | 2.79 | 12.5 | 18.23 |
| Low Estimate | 2.22 | 2.45 | 11.86 | 14.65 |
| High Estimate | 2.78 | 3.07 | 13.5 | 21.01 |
| Year Ago EPS | 1.62 | 2.11 | 6.32 | 12.5 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 15 | 13 | 25 | 25 |
| Avg. Estimate | 8.93B | 9.88B | 41.44B | 51.53B |
| Low Estimate | 8.51B | 9.56B | 40.4B | 45.94B |
| High Estimate | 9.23B | 10.33B | 43.57B | 55.87B |
| Year Ago Sales | 6.96B | 8.31B | 34.12B | 41.44B |
| Sales Growth (year/est) | 28.30% | 18.90% | 21.40% | 24.40% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 1.73 | 1.98 | -0.13 | 2.22 |
| EPS Actual | 1.62 | 2.11 | 0.1 | 2.49 |
| Difference | -0.11 | 0.13 | 0.23 | 0.27 |
| Surprise % | -6.40% | 6.60% | 176.90% | 12.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 2.47 | 2.79 | 12.5 | 18.23 |
| 7 Days Ago | 2.5 | 2.76 | 12.47 | 18.24 |
| 30 Days Ago | 2.55 | 2.76 | 12.51 | 18.21 |
| 60 Days Ago | 2.24 | 2.43 | 11.03 | 15.94 |
| 90 Days Ago | 2.48 | 2.63 | 12.39 | 17.7 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 3 | 3 | 3 |
| Up Last 30 Days | 1 | 6 | 4 | 7 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 4 | 1 | 2 | 2 |
Growth Estimates
| CURRENCY IN USD | LLY | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 52.50% | -- | -- | 1.60% |
| Next Qtr. | 32.20% | -- | -- | 10.50% |
| Current Year | 97.80% | -- | -- | 5.20% |
| Next Year | 45.80% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 50.67% | -- | -- | 11.22% |
| Past 5 Years (per annum) | -4.62% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/18/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/15/2024 |
| Maintains | Goldman Sachs: Neutral to Neutral | 4/11/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/5/2024 |
| Upgrade | Erste Group: Hold to Buy | 4/3/2024 |
| Maintains | Citigroup: Buy to Buy | 4/2/2024 |
Related Tickers
JNJ Johnson & Johnson
147.91
+1.49%
PFE Pfizer Inc.
26.00
+2.40%
ABBV AbbVie Inc.
166.41
+1.06%
MRK Merck & Co., Inc.
125.78
+0.44%
AMGN Amgen Inc.
268.93
+2.35%
BMY Bristol-Myers Squibb Company
48.93
+1.30%
GILD Gilead Sciences, Inc.
66.76
+0.91%
BIIB Biogen Inc.
194.38
+2.03%
AZN AstraZeneca PLC
68.55
+0.28%
NVS Novartis AG
94.36
+1.93%